Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALPL | P05186 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | CA12 | O43570 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.51 |
| ▸ | CA9 | Q16790 | 5/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38656746 | 1.00 | HTT (0.63) | HTTTDP1ALPLCA2CA12 | |
| SCHEMBL5188245 | 0.87 | TDP1 (0.61) | HTTTDP1CA2CA12CA1 | |
| SCHEMBL1098646 | 0.85 | HTT (0.60) | HTTTDP1ALPLPKMLMNA | |
| SCHEMBL17373258 | 0.84 | HTT (0.58) | HTTTDP1ALPLPKMLMNA | |
| SCHEMBL282513 | 0.84 | HTT (0.58) | HTTTDP1ALPLPKMLMNA | |
| SCHEMBL10035010 | 0.83 | CYP19A1 (0.47) | HTTCA2CA12CA1CA9 | |
| SCHEMBL3573840 | 0.83 | HTT (0.57) | HTTTDP1ALPLPKMLMNA | |
| SCHEMBL11588839 | 0.82 | HTT (0.60) | HTTTDP1ALPLCA2CA12 | |
| SCHEMBL16305322 | 0.81 | ALPL (0.60) | HTTTDP1ALPLCA2CA12 | |
| SCHEMBL31195232 | 0.81 | ALDH1A1 (0.61) | HTTTDP1ALPLPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267276-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2022-08-25 | — | — | US | disclosed |
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| CN-113613721-A | NLRP modulators | 诺华股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3817817-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| EP-3817815-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| CN-112584899-A | NLRP modulators | 诺华股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2594554-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1594866-A1 | ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES | PFIZER INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1530574-A1 | MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-18 | — | — | EP | disclosed |
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | SCHERING AG (DE) | 2004-10-21 | — | — | US | disclosed |
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004072070-A1 | ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES | PFIZER INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004026881-A1 | MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-01 | — | — | WO | disclosed |
| US-4211776-A | ANTIEMETICS | CHOAY S.A. (FR) | 1980-07-08 | — | — | US | disclosed |
| US-4132786-A | ANTIEMETICS, ANTICONVULSANTS, ANESTHETICS, ANTIBIOTICS | MOREAU ROBERT C | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395241-A1 | NLRP MODULATORS | NLRP1, NLRP3, NOD1 | HTT 3312/4885TDP1 2236/4885ALPL 4547/4885 |
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | CCNK, CDK2, CDK1 | HTT 4545/4885TDP1 1454/4885ALPL 4580/4885 |
| US-20220267276-A1 | NLRP MODULATORS | NLRP1, NRP1, NR4A3 | HTT 3620/4885TDP1 3380/4885ALPL 3939/4885 |
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | MKI67, TK1, CDK2 | HTT 3024/4885TDP1 1624/4885ALPL 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.